Market Exclusivity Needed For Special Condition Switches – Expert
This article was originally published in The Pink Sheet Daily
Without market exclusivity and a requirement to make generics also subject to consumer access restrictions, drug firms likely will not invest in novel switches, says a switch process veteran and Merck Consumer Care executive.
You may also be interested in...
FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
The questions FDA poses for a March 22-23 hearing indicate the agency is delving into greater detail than in its previous discussions of alternative routes to access pharmaceutical treatments. FDA says decisions would be made case by case, but refers to treating conditions including high cholesterol, high blood pressure, migraines and asthma.
Behind-The-Counter Guidance Stalled, But Interest Grows To Expand Access
FDA executives say behind-the-counter status for nonprescription drugs resonates in discussions at the agency, but a former deputy commissioner says the agency's BTC interests are stifled by not having explicit authority